Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II Study of CB-839 and Capecitabine in Patients With Advanced Solid Tumors and Fluoropyrimidine Resistant PIK3CA Mutant Colorectal Cancer

NCT02861300 is registered in ClinicalTrials.gov with David Bajor, MD as lead sponsor.

NCT NCT02861300
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02861300 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II Study of CB-839 and Capecitabine in Patients With Advanced Solid Tumors and Fluoropyrimidine Resistant PIK3CA Mutant Colorectal Cancer
Lead sponsor
David Bajor, MD
Phase
Phase 1/2
Overall status
Completed
Start date
September 12, 2016
Completion date
January 10, 2023
Enrollment
50 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

colon cancer, colorectal cancer, rectal cancer, solid tumor